Navigation Links
Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
Date:11/19/2007

Poster presentation highlights response rate in subset of patients with

Anaplastic Gliomas

NEW YORK, Nov. 19 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that early results of a phase II single agent trial of perifosine (KRX-0401) in patients with recurrent malignant gliomas was presented in a poster presentation on Saturday, November 17, 2007 at the 12th Annual Scientific Meeting of the Society for Neuro-Oncology, held in Dallas, Texas. The poster, entitled "A Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas, provided an update on the clinical activity of single agent perifosine in patients with malignant glioblastoma (GBM) and malignant anaplastic gliomas (AA).

Ph II Study - Interim Results

Twenty-five patients with advanced malignant gliomas were treated with a loading dose of 600 mg (150mg x 4) followed by 100 mg daily dose of perifosine. Patients must have failed prior radiation therapy and have shown unequivocal evidence for tumor progression by MRI or CT scan. There was no limitation on the number of prior relapses or prior therapies and patients with a KPS greater than or equal to 50 were eligible. Patients were not allowed to take enzyme-inducing anti-epileptic drugs (EIAED's). Response was measured by the MacDonald Criteria (PR greater than or equal to 50% decrease in bidirectional tumor area and SD = between 25% worse to 50% better). Patients were broken out into two groups with results as follows:

Malignant Glioma N Evaluable Partial Stable Overall (PR

Response Disease + SD)

All Patients 25 20
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Pot bellies linked to early signs of cardiovascular disease
2. Eye-staining technique offers early detection for dry eye syndrome
3. Early Weight Loss in Women Linked to Dementia
4. Isolation of a new gene family essential for early development
5. U of M study: Early treatment can reverse heart damage
6. Gerresheimer to be Included in the SDAX Early Decision on Inclusion in the MDAX on September 5, 2007
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Pop stars more than twice as likely to die an early death
9. Exercise and yoga improves quality of life in women with early-stage breast cancer
10. Research says doctors gender may hinder early diagnosis of heart disease in women
11. Antidepressant shows early promise in treating agitation and psychotic symptoms of dementia
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Schumacher Homes Builds St. Jude Dream Home(R) 2Health News:InfoLogix Launches Strategic Mobility Assessment Service for Hospitals 2Health News:InfoLogix Launches Strategic Mobility Assessment Service for Hospitals 3Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 2Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 3Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 4Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 5Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 6Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 7Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 8Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 9Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 2Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 3Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 4Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 5Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 6Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 7Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 8Health News:Sentrx Growth Continues with Four New Clients in Second Quarter 2Health News:Sentrx Growth Continues with Four New Clients in Second Quarter 3
Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5Banfield The Pet Hospital 28R 29 Welcomes Board Certified Nutritionist Medical Specialist to Practice 61622 1Banfield The Pet Hospital 28R 29 Welcomes Board Certified Nutritionist Medical Specialist to Practice 61622 2Banfield The Pet Hospital 28R 29 Welcomes Board Certified Nutritionist Medical Specialist to Practice 61622 3Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 61619 1Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 61619 2Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 61619 3Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Onco 14899 1Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Onco 14899 2Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Onco 14899 3Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Onco 14899 4